Dechra's high price defence

Dechra Pharmaceuticals (DPH) spent most of the first half integrating its €135m (£110m) Eurovet acquisition. That should ultimately mean cost savings totalling £4m through the rationalisation of different manufacturing sites. However, Dechra's performance will be weighted to the second half of the year, as it deals with a variety of operational issues in its main business divisions that have arisen from its acquisition strategy.

To continue reading, register today

to enjoy limited access to the following:

  • Daily trading news
  • Funds coverage
  • Features on big investment themes
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics